FDA approves a new generic valsartan | FDA
WEBToday, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure.
FDA Statement on FDA’s ongoing investigation into valsartan …
WEBValsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA currently has a major operation underway to investigate and …
Valsartan Lawsuit Settlement Nears for Hetero, But Fight
WEBJun 18, 2024 · Lawyers are nearing a settlement agreement for those who sued Hetero, a manufacturer of valsartan, a generic blood pressure medication tainted with carcinogens.
New Details Revealed About Blood Pressure Medicine Recalled
WEBJun 19, 2023 · The U.S. Food and Drug Administration is being accused of not doing enough to ensure carcinogens aren’t contaminating drugs during the manufacturing process. Valsartan was recalled worldwide in 2018 following studies that found the blood pressure medication contained unacceptable amounts …
FDA provides update on its ongoing investigation into valsartan ...
WEBThe U.S. Food and Drug Administration is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recall of several drug products containing …
A new drug shows potential benefits in the recovery of patients …
WEBMay 14, 2024 · In this context, Sacubitril/Valsartan is a combination drug that has achieved promising results in reducing the rehospitalization rates and cardiovascular deaths in patients with heart failure.
After multiple recalls, FDA approves new generic for valsartan
WEBMar 13, 2019 · The U.S. Food and Drug Administration has approved a new generic of the blood pressure medication valsartan to help alleviate a recent shortage due to multiple safety recalls.
Valsartan Lawsuit: Cancer Claims & Latest Lawsuit Updates
WEBSep 3, 2024 · People filing valsartan lawsuits claim they developed cancer or liver damage after taking valsartan drugs contaminated with N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). The FDA classifies NDMA and NDEA as probable human carcinogens, which means they can potentially cause cancer.
Exposure to Valsartan Products Containing Nitrosamine …
WEB1 day ago · Background Following the mass recall of valsartan products with nitrosamine impurities in July 2018, the number of patients exposed to these products, the duration of exposure, and the potential for...
FDA Statement on the FDA’s ongoing investigation into valsartan …
WEBFDA scientists estimate that if 8,000 people took the highest daily valsartan dose (320 mg) that contained NDMA, for four years (the time we think the affected products had been …
- Some results have been removed